Arax Advisory Partners’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
KWM
FCBT
EP
Arax Advisory Partners's XPH Position: Q2 2026 in Review
Arax Advisory Partners increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 1,353% in Q2 2026, buying an estimated $828K and bringing the position to 15,179 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1217.
Arax Advisory Partners first reported a position in XPH in Q1 2026 and has held it in 2 quarters since. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.
- Arax Advisory Partners held 15,179 shares of State Street SPDR S&P Pharmaceuticals ETF worth $1.01M as of Q2 2026.
- Arax Advisory Partners bought 14,134 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $828K.
- State Street SPDR S&P Pharmaceuticals ETF made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1217 holding.
- Arax Advisory Partners first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2026 and has held it in 2 quarters since.
- 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.